Research Roundup

smart light bulb on orange background
Debbie Rigby rounds up the latest in research news  Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease Analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial provides more evidence of the renoprotective effects of SGLT2 inhibitor empagliflozin in patients with type 2 diabetes and cardiovascular disease.

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous CWH: location rules "indefensible, nonsensical"
Next Weekly Dose: Methylprednisolone